- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01797952
A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation (mucositis)
A Randomized Double Blind Placebo Controlled Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation
The study will be conducted at departments of Medical Oncology and Hematology, All India Institute of Medical Sciences (AIIMS).
Patients with various malignancies who are taken up for high dose chemotherapy followed by stem cells transplant (blood and marrow transplant) have very high chances of developing severe oral mucositis (generally 60-80% in different studies and our own previous experiences). This not only causes significant morbidity but also hampers quality of life needing use of parenteral nutrition, analgesics, and antibiotics.
No definite treatment exists for prevention or treatment of oral mucositis in this group of patients. Though one study has suggested that use of IV palifermin (a keratinocyte growth factor) will reduce duration and severity. Palifermin is very expensive and not available in country. Recently investigators have shown effectiveness of a probiotic Lactobacillus CD 2 in reducing incidence and severity of chemo-radiotherapy induced mucositis in head and neck squamous cell cancer patients. (Published online in European Journal of Cancer: http://dx.doi.org/10.1016/j.ejca.2011.06.010)European Journal of Cancer 2012;4:875-881.No significant toxicity has been reported with its use.
A pilot study on similar aspect was completed recently at our center(Clinical trial.gov identifier:NCT 01480011) and in 31 patients who received this only 6 (20%) developed grade III or IV Mucositis. Now, investigators want to study the efficacy of this drug to reduce severity of mucositis in patients undergoing myeloablative hematopoietic stem cell transplantation. The study drug and placebo will be supplied by CD Pharma India Private Limited.
Investigators further give undertaking that study will be carried as per GCP and declaration of Helsinki.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Design Placebo controlled double blind randomized, multi center clinical trial.
Study Population and Number of Subjects Total of 108 patients undergoing myeloablative allogeneic or autologous hematopoietic stem cell transplantation and receiving high-dose chemotherapy as conditioning regimen at AIIMS (departments of Medical Oncology and Hematology) will be enrolled for the study and will be equally divided in two groups (drug and placebo).
Study Center The study will be carried at Departments of Medical Oncology and Hematology of All India Institute of Medical Sciences, New Delhi, India.
More centers are likely to be added.
Study Objectives To test whether the probiotic Lactobacillus CD2 (drug) lozenges can reduce the incidence and severity of conditioning therapy induced oral mucositis in patients undergoing haematopoietic stem cell transplantation.
Investigational Product Drug: The trial medication is in the form of lozenge, which is supposed to be dissolved by itself in mouth.
It contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient.
Placebo: The placebo is a mix of sugars and salts used as excipients in the active formulation.
Note: Placebo and drug lozenges will be similar in physical appearance and color.
Dose of Study drug The daily dose of trial medications will be 4-6 lozenges per day, one lozenge to be taken every 2-3 hours preferably not before the meal. The lozenge should be kept in mouth for it to dissolve by itself. A hot beverage (e.g. tea, coffee, milk etc.) should not be taken for at least half an hour before and after the medication since elevated temperature can inactivate the bacteria.
Duration of treatment The treatment will start 4-7 days before starting chemotherapy for conditioning regime of HSCT and will continue till resolution of mucositis or Day+24 post stem cell infusion which-ever is earlier.
Efficacy Assessments
Clinical activity will be defined as reduction in the incidence and severity of chemotherapy induced mucositis in HSCT patients. Most recent version of CTCAE; clinical score of CTC V4.03 ( as also outlined in CTCAE version 3.0) will be used for mucositis assessment. Also,WHO and Oral Mucositis assessment score will be recorded. The study will have the following primary and secondary endpoints:
Primary endpoint
1. Determine the incidence of grade III and IV mucositis in patients undergoing allogeneic or autologous haematopoietic stem cell transplantation in two groups.
Secondary endpoint
- Determine the incidence of all Grade of mucositis in patients undergoing allogenic or autologous haematopoietic stem cell transplantation in two groups.
- Duration of and time period for healing of chemotherapy induced oral mucositis.
- Determine incidence and severity of dysphagia and requirement of IV antibiotics in two groups
Safety Assessments
- Medical History
- Physical Examination
- Vital Signs (blood pressure, pulse rate and respiratory rate)
- Laboratory Examinations
- Adverse Events
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Delhi
-
New delhi, Delhi, India, 110029
- Institute Rotary Cancer Hospital,All India Institute of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 10 and 70 years.
- Karnofsky Performance Score ≥ 70%.
- Confirmed histological diagnosis of cancer/leukaemia for which haematopoietic stem cell transplantation is as approved modality of therapy.
- Patients eligible to receive high-dose chemotherapy as part of conditioning regime.
- Concomitant co morbid condition if present, controlled by medicines.
- Serum creatinine upto 1.8mg/dl.
- Total bilirubin 2mg/dl.
- Liver enzymes within three times of normal limit.
- Expected survival > 6 months.
Exclusion Criteria:
- Pregnant women and lactating mothers.
- Patients with history of AIDS
- Patients who have taken any other investigational product in last 4 weeks.
- Patients having untreated symptomatic dental infection.
- Patients with WHO Grade 3 or 4 oral Mucositis.
- Other serious concurrent illness.
- Inconclusive histological diagnosis.
- Patients on anticancer antibiotics.
- Patients with signs and symptoms of systemic infections.
- Patient's/guardian's refusal to sign informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Lactobacillus CD 2 lozenges
2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
|
2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
The placebo is a mix of sugars and salts used as excipients in the active formulation
|
Placebo Comparator: Placebo lozenges
The placebo is a mix of sugars and salts used as excipients in the active formulation
|
2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
The placebo is a mix of sugars and salts used as excipients in the active formulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of mucositis grade(Common Terminology Criteria of Adverse Events (CTCAE) and World health Organization (WHO)
Time Frame: Day 0-Days 24
|
1. Determine the incidence of grade III and IV mucositis in patients undergoing allogeneic or autologous haematopoietic stem cell transplantation in two groups
|
Day 0-Days 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence,duration and time period of mucositis Common Terminology Criteria of Adverse Events (CTCAE) and World health Organization (WHO)
Time Frame: Day 0-Days 24
|
1. Determine the incidence of all Grade of mucositis in patients undergoing allogenic or autologous haematopoietic stem cell transplantation in two groups (Criteria for assessment is given in Appendix 1).
|
Day 0-Days 24
|
Incidence,duration and time period of mucositis Common Terminology Criteria of Adverse Events (CTCAE) and World health Organization (WHO)
Time Frame: Day0- days 24
|
Duration of and time period for healing of chemotherapy induced oral mucositis.
|
Day0- days 24
|
Incidence,duration and time period of mucositis Common Terminology Criteria of Adverse Events (CTCAE) and World health Organization (WHO)
Time Frame: day 0- days 24
|
Determine incidence and severity of dysphagia and requirement of IV antibiotics in two groups
|
day 0- days 24
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety assessment
Time Frame: D0-D24
|
1 Vital Signs (blood pressure, pulse rate and respiratory rate) 2 Laboratory Examinations 5 Adverse Events
|
D0-D24
|
Collaborators and Investigators
Investigators
- Principal Investigator: Atul Sharma, MD,DM, All India Institute of Medical Sciences, New Delhi
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P 1201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Mucositis in Patients Undergoing HSCT
-
Medical University of GrazRecruiting
-
Yonsei UniversityCompletedPatients Undergoing Endoscopic Retrograde Cholangiopancreatography in Prone PositionKorea, Republic of
-
Cairo UniversityNorhan Abdelaleem Ali; Ahmed Shaker Ragab; Yasmina sayed Abdrabo IsmaelCompletedComparing of 2 Different Volumes in ESPB in Patients Undergoing MRMEgypt
-
Minia UniversityCompletedUnilateral TAP Block in Pediatric Patients Undergoing Lower Abdominal SurgeryEgypt
-
Institute of Hematology & Blood Diseases HospitalNot yet recruitingThe Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
-
Cairo UniversityMohamed, Ahmed A., M.D.; Tarek Ahmed Radwan; Mohamed Mahmoud Mohamed; ismaiel saied...CompletedDexmedetomidine VS Fentanyl as Adjuvants to Epidural Bupivacaine in Patients Undergoing Lumbar Spine SurgeriesEgypt
-
NycomedCompletedControl of Local Bleeding in Patients Undergoing Prostatectomy.Denmark
-
Universitair Ziekenhuis BrusselCompletedSpontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing IUIBelgium
-
Alexandria UniversityCompletedAnalgesic Efficacy of M-TAPA Block Accomplished Prior to Surgery in Patients Undergoing Laparoscopic Gynecological SurgeriesEgypt
-
B. Braun Melsungen AGCompletedAdult Patients in Need of High-energy Oral Nutritional SupplementationUnited Kingdom
Clinical Trials on Lactobacillus CD 2
-
All India Institute of Medical Sciences, New DelhiCompleted
-
S. Andrea HospitalUnknown
-
Medtronic Spinal and BiologicsCompleted
-
Medtronic Spinal and BiologicsCompletedDegenerative Disc Disease
-
Michael Rapoff, Ph.D.National Institute of Neurological Disorders and Stroke (NINDS)Completed
-
Medical College of WisconsinChildren's Hospital of PhiladelphiaCompletedMalignant Diseases (ie, Leukemia, MDS, Lymphoma) | Non-malignant Diseases (ie, Bone Marrow Failure Syndromes)United States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular DiseaseUnited States
-
Mashhad University of Medical SciencesTerminatedInteractive CD-based Education
-
Procter and GambleCompleted
-
Nile TherapeuticsCompletedAcute Decompensated Heart FailureUnited States, Germany, Israel